- Fund Type: Open-End Fund
- Objective: Region Fund-Nordic
- Asset Class: Equity
- Geographic Focus: Nordic Region
Meitav Dash 0B Bond Platinum Duration Up To 3 Years
+ Add to WatchlistAPXSCAN:IT
65.55 ILs 0.09 0.14%As of 00:59:30 ET on 05/23/2013.
Snapshot for Meitav Dash 0B Bond Platinum Duration Up To 3 Years (APXSCAN)
| Year To Date: | +4.10% | 3-Month: | +0.18% | 3-Year: | +5.86% | 52-Week Range: | 56.70 - 65.64 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +0.83% | 1-Year: | +12.57% | 5-Year: | -11.73% | Beta vs TA-100: | 0.49 |
Fund Profile & Information for APXSCAN
Meitav Dash 0B Bond Platinum Duration Up To 3 Years is an open-end fund registered in Israel.
| Inception Date: | 12-29-2005 | Telephone: | - |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | - | ||
Fundamentals for APXSCAN
| NAV | (on 2013-05-23) 65.55 |
|---|---|
| Assets (M) | (on 2013-04-30) 170.90 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for APXSCAN
No dividends reported
Fees & Expenses for APXSCAN
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | 0.87 |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for APXSCAN
Filing Date: 01/31/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| ISRELE 6 ½ 02/20/15 | 6,202 | 8,168,025 | 6.406% |
| CELIT 6 ¼ 01/05/17 | 4,152 | 4,401,964 | 3.453% |
| MAKAM 0 06/05/13 | 4,090 | 4,066,384 | 3.189% |
| EZRAIT 6 05/31/15 | 2,549 | 2,950,314 | 2.314% |
| KVCLIT 5.3 10/30/16 | 1,518 | 1,919,584 | 1.506% |
| EDRIIT 5.1 07/10/17 | 1,670 | 1,787,155 | 1.402% |
| DLEKG 6.1 05/01/16 | 1,723 | 1,785,268 | 1.400% |
| DLEKG Float 08/31/18 | 1,938 | 1,782,580 | 1.398% |
| GZTIT 6.4 01/01/17 | 1,640 | 1,773,238 | 1.391% |
| MEGOIT 5 ½ 03/31/16 | 1,399 | 1,594,486 | 1.251% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page